Medical Therapeutics

MuscleMatrix

Brief Description

MuscleMatrix is developing a hydrogel that could change how medics treat traumatic injuries on the battlefield, as well as revolutionize surgical repairs for civilians with soft tissue injuries. Traumatic and surgical injuries of soft tissue that involve underlying skeletal muscle remain one of the greatest challenges to tissue reconstruction. Severe injuries, such as those involving the loss of a substantial portion of muscle tissue, are not capable of healing on their own and are referred to as volumetric muscle loss (VML) injuries. By definition, VML results in...

Vivere Oncotherapies

Brief Description

Gene and cell therapies for cancer.

Timeline 2024. Company founded. Inventors

Adam Schieferecke, John Dueber, David Schaffer, Juan Eduardo Hurtado, Hyun-Cheol Lee

Algen Biotechnologies

Brief Description

Algen Biotechnologies is building a next-generation, functional genomics-based platform for the discovery of novel therapeutics for cancers with high unmet need. Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery. The company's biologists and data scientists are collaborating to deliver innovative, patient-centric medicines for the toughest-to-treat diseases.

The company was founded to commercialize technology developed at UC Berkeley while Algen Biotechnologies CEO...

Tessera Therapeutics, Inc.

Brief Description

Developer of gene writing technology designed to permanently make small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve their lives.

Tessera Scientific Advisory Board Member David Schaffer co-invented the company's foundational technology as UC Berkeley Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell...

ReRx Therapeutics

Brief Description

ReRx is developing novel oral therapeutics to treat patients with severe metabolic diseases including obesity, metabolic syndrome, diabetes, and liver diseases. The company's therapeutics target metabolic pathways involved in regulating energy homeostasis and improve treatment outcomes compared to similar pharmacological agents.

Timeline 2023. Company founded; Joins Berkeley Skydeck Cohort 17 Inventors

Chi Zhu, Anders Michael Naar, Justin Yu-Sun Lee

AsparaGlue

Brief Description

AsparaGlue has developed a superglue-like medical adhesive for external wound closure and internal tissue adhesion. The proprietary technology is the world’s only biocompatible and biodegradable medical superglue.

Timeline 2023. Company founded; joins Berkeley Skydeck accelerator, cohort 16 Inventors

Philip Messersmith, Subhajit Pal, Ji Soo Shin, Kelsey Gray DeFrates

Resvita Biosciences

Brief Description

Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.

Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced...

Inapill

Brief Description

Inapill is developing novel therapeutics that tune immune cell metabolism (immunometabolism) to treat diseases caused by immune system overactivation and excessive inflammation.

Timeline 2023. Company founded; tenant at Bakar Labs, in the UC Berkeley Bakar BioEnginuity Hub Inventors

Kaoru Saijo, Greg Timblin

Lyterian Therapeutics, Inc.

Brief Description

Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets. Lyterian is derived from λυτήριος or lutḗrios, which means termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. Lyterian Therapeutics medicines are inspired by the logic that orchestrates homeostatic equilibria and drives healing.

Timeline 2022....

Elenae Therapeutics

Brief Description

Applying antisense oligonucleotide technology to target coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

Timeline 2021. Company founded Inventors

Anders Naar, Sakari Kauppinen